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Abstract
Hyperinsulinemia affects 72% of Fanconi anemia (FA) patients and an additional 25% expe-
rience lowered glucose tolerance or frank diabetes. The underlying molecular mechanisms
contributing to the dysfunction of FA pancreas β cells is unknown. Therefore, we sought to
evaluate the functional role of FANCA, the most commonly mutated gene in FA, in glucose-
stimulated insulin secretion (GSIS). This study reveals that FANCA or FANCB knockdown
impairs GSIS in human pancreas β cell line EndoC-βH3. To identify potential pathways by
which FANCA might regulate GSIS, we employed a proteomics approach to identify FANCA
protein interactions in EndoC-βH3 differentially regulated in response to elevated glucose
levels. Glucose-dependent changes in the FANCA interaction network were observed,
including increased association with other FA family proteins, suggesting an activation of
the DNA damage response in response to elevated glucose levels. Reactive oxygen spe-
cies increase in response to glucose stimulation and are necessary for GSIS in EndoC-βH3
cells. Glucose-induced activation of the DNA damage response was also observed as an
increase in the DNA damage foci marker γ-H2AX and dependent upon the presence of reac-
tive oxygen species. These results illuminate the role of FANCA in GSIS and its protein
interactions regulated by glucose stimulation that may explain the prevalence of β cell-spe-
cific endocrinopathies in FA patients.
Introduction
Fanconi anemia is a rare disease with 22 complementation groups representing mutations in
individual genes. Numerous abnormal physical and molecular phenotypes are associated with
this disease, most notably bone marrow failure (BMF), acute myelogenous leukemia (AML)
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and a spectrum of other malignancies that contribute to patient mortality. Approximately 90%
of FA patients will experience BMF as their first hematopoietic presentation of disease and an
AML incidence rate of 33% by age 40 [1]. FA patients also display a spectrum of congenital
defects, such as microcephaly, malformed or absent thumbs, short stature, and skin discolor-
ations [2]. Up to one-third of FA patients exhibit no physically discernable characteristic.
Advances in hematopoietic cell transplant (HCT) therapy in FA patients have significantly
reduced the mortality associated with AML [2, 3], yet these patients remain prone to a spec-
trum of cancers including breast, head and neck, and genitourinary cancers [4].
In addition, 80% of all FA individuals exhibit at least one endocrine abnormality, such as
growth hormone deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothy-
roidism, hypogonadism, or infertility [5]. The prevalence of diabetes in FA patients is 8–10%,
and up to 68% of FA patients exhibit impaired glucose tolerance [5–10]. Both FA and the treat-
ment of its associated BMF with hematopoietic cell transplantation (HCT) increase the risk of
developing diabetes [11–13]. It was also found that 25% of post-HCT FA patients have reduced
first-phase insulin release [14], which may lead to diabetes development. However, FA patients
have a high likelihood of developing diabetes even before HCT [9, 10], suggesting the underly-
ing cause of the elevated rates of endocrinopathies in FA patients is not entirely related to
these treatments. Islet cell death can be caused by chronic hyperglycemia, referred to as glucose
toxicity [15–17]. FA patients have a propensity for hyperglycemia that originates due to either
β cell dysfunction or insulin resistance [5]. The cause of these abnormalities is unknown but
has been postulated to be caused by several factors, including increased reactive oxygen species
(ROS)-mediated damage to β cells [18–20], iron overload in patients receiving transfusions, or
medications commonly used to treat FA patients (androgens & corticosteroids) [5]. Therefore,
it is reasonable to assume that FA proteins possess undiscovered functions in β cells that might
affect insulin secretion. Understanding the role of FA proteins in pancreas β cell function
would help develop strategies to reduce this prevalent co-morbidity in FA patients.
Controlling pancreatic endocrinopathies is important for the overall health of FA patients
because it has the potential to prevent adverse outcomes to therapies used to treat FA [9]. For
instance, hyperglycemia negatively impacts clinical outcome and survival after HCT through
increased risk of septicemia, graft versus host disease, and death in pediatric and adult patients
[21–24]. Current therapies for FA patients with normal fasting glucose but impaired glucose
tolerance show varying levels of success [5]. Therefore, significant research efforts are needed
to understand the molecular mechanisms by which FA mutations predispose these patients to
endocrinopathies so that improved treatment and monitoring protocols can be developed to
reduce these comorbidities and enhance FA patient outcomes after HCT.
The aim of this study was to evaluate the role of FANCA in GSIS and evaluate its interac-
tome in pancreas β cells and the effect of glucose stimulation on these interactions. GSIS is
controlled by many factors including non-glucose nutrients, hormones, and neural inputs, but
can be measured by analyzing the amount of insulin secreted from β cell following glucose
stimulation [25]. In this study, we have determined that inhibition of FANCA or FANCB pre-
vents GSIS in EndoC-βH3 cells. To evaluate the role of FANCA in GSIS, we established the
protein-protein interactome of endogenous FANCA in both EndoC-βH3 cells and identify β
cell-specific FANCA interactions differentially regulated by glucose stimulation, including the
assembly of the FA complex. Furthermore, we demonstrate that ROS production is required
for insulin secretion in EndoC-βH3 cells and responsible for the increase in DNA damage
marked by γ-H2AX levels and the assembly of FA protein interactions with FANCA following
glucose stimulation.
FANCA regulation of insulin secretion
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Materials and methods
Cell lines
Human embryonal kidney 293FT cell line (ThermoFisher) was cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM) (Corning), containing 10% fetal bovine serum (Atlanta Biologi-
cals) and 1% penicillin-streptomycin (Corning). Human pancreatic islet EndoC-βH3 cell line
was obtained from Univercell-Biosolutions. Cells were seeded at the density of 70000/cm2
onto Matrigel (4 μl/cm2)-fibronectin (2 μg/cm2)-coated TPP plates (Midwest Scientific) and
cultured in Optiβ1 medium (Univercell-Biosolutions), containing 10 μg/mL puromycin and
1% penicillin-streptomycin. Cells were treated with 1 μM 4-hydroxytamoxifen, twice a week
for the period of 3 weeks, per the supplier’s instructions. After 3 weeks of treatment, complete
cell proliferation arrest was observed, and tamoxifen was removed from the medium and all
following experiments were conducted within the following 2 weeks. Human pancreatic can-
cer MiaPaCa-2 (CRL-1420) cell line (ATCC) was cultured in DMEM, containing 10% fetal
bovine serum, 2.5% horse serum and 1% penicillin-streptomycin.
Co-immunoprecipitation of FANCA complexes
Cells were lysed using NETN lysis buffer with the protease and phosphatase inhibitors as
described above. The volume of buffer used for each sample was 3 times of the cell pellet size.
Sample protein concentrations were measured using BCA Protein Assay kit (ThermoFisher).
Identification and analysis of FANCA interacting proteins in 293FT, EndoC-βH3 and Mia-
PaCa-2 cells was done using Dynabeads Antibody Coupling Kit (ThermoFisher). Anti-
FANCA antibodies (60 μg) (Bethyl Laboratories) were coupled onto magnetic beads (3 mg) at
37 ºC overnight, with rotation. The same amount of rabbit polyclonal IgG (Santa Cruz Bio-
technology) was coupled to beads and used as a negative control. Beads were thoroughly
washed with buffers provided within the kit and incubated with 3 mg of proteins from the cell
lysates for 2 h at 4˚C, with rotation. To remove the non-specific binders, beads were washed 4
times with NETN buffer containing 50 mM NaCl and 1 mM MgCl2. Then, they were washed
once with NETN containing 0.02% Tween, for 5 min with rotation. To elute the bound protein
fraction, beads were incubated with 500 μL 0.5 M NH4OH/0.5 mM EDTA, pH 11.0, for 10
min with rotation. The eluted fraction was neutralized with acetic acid, concentrated using a
SpeedVac and submitted to gel electrophoresis.
Protein electrophoresis
For the mass spectrometry experiments, 10% Criterion XT Bis-Tris Protein Gels (Bio-Rad)
were used for the protein electrophoretic separation with a compatible XT MOPS (3-(N-mor-
pholino)propanesulfonic acid) running buffer (Bio-Rad). For the immunoblot experiments,
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using either 6% or
12% gels was used for the protein separation and detection.
Protein in-gel digestion
After electrophoretic protein separation, gels were stained with Coomassie Brilliant Blue G-
250 dye (ThermoFisher) for 2 h and left to destain overnight in the destain solution (10% acetic
acid/20% methanol). The destained gel pieces were incised, washed with HPLC water and
dehydrated with neat acetonitrile (ACN). Proteins were reduced with 2 mM Tris(2-carbox-
yethyl)phosphine (TCEP) in 50 mM ammonium bicarbonate (NH4HCO3, AmBic) for 1 h at
37˚C and then dehydrated with ACN. The reduced proteins were alkylated with 50 mM iodoa-
cetamide (IAA)/50 mM AmBic, for 20 min in dark with rotation. The gel pieces were
FANCA regulation of insulin secretion
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dehydrated again with ACN to remove all the reagents. MS-grade trypsin (10 ng/μL) (Pro-
mega) was added to the samples and incubated for 30 min on ice. After the excess of trypsin
was removed from tubes, 25 mM AmBic was added to cover the gel pieces and incubate over-
night at 37˚C. Digested peptides were then extracted from the gel with 50% ACN/0.1% tri-
fluoroacetic acid solution. Samples were dried in a SpeedVac, re-dissolved in 15 μL 0.1%
formic acid and submitted for LC-MS/MS analysis.
Mass spectrometry
In-gel digested peptide samples were analyzed using either the Orbitrap Elite, Orbitrap Q
Exactive HF, or Orbitrap Fusion Lumos. The Q Exactive HF and Fusion Lumos instruments
were coupled with UltiMate 3000 RSLCnano LC systems (Thermo Scientific) and the Elite
with the Eksigent Ultra NanoLC 2D with nanoflex cHiPLC. For the Q Exactive HF, online
peptide separation was carried out by first desalting peptides for 3 min on a trapping col-
umn (C18 Pepmap100 0.3x5 mm, 5 μm, 100A) at 5 μL/min in 1% acetonitrile, 0.1% formic
acid before separation into the mass spectrometer using a 75 μm x 25 cm peptide CSH C18
130A, 1.7 μm nano-column (Waters Corp, Milford, MA) using a linear gradient run at 300
nL/min from 4% B to 45% B over 85 min. Solvents: A is water + 0.1% formic acid, and B is
80% ACN + 0.1% formic acid. The total run time was 105 min. The Q Exactive HF was run
in a top 12 data-dependent acquisition mode triggering on peptides with charge states 2 to 4
over the mass range of 197–1500 m/z with MS1 resolution set to 120,000, AGC target of 3e6
and a maximum ion time of 60 ms. MS2 resolution was set to 15,000, AGC target of 1e5 and
a maximum ion time of 250 ms. Dynamic exclusion was 12 s for a low complexity sample,
quadrupole isolation width 1.6 m/z, spray voltage 1.9 kV, capillary temperature 275˚C and a
normalized collision energy of 28. The minimum AGC target and the intensity threshold
were set to 5e3 and 2e4, respectively. For analysis with the Orbitrap Elite, around 5 μL (500
ng) of each sample was loaded on a cHiPLC column (0.5 mm C18 CL 3 μm 120 Å trap col-
umn, Eksigent) using 0.1% formic acid and fractionated with an analytical column (75 μm x
15 cm C18 CK 3 μm 120 Å ChromXP, Eksigent). The samples were eluted using a 60 min
linear gradient of ACN (0–60%) in 0.1% formic acid. The parameters for the method cre-
ated were: nanospray needle voltage in positive mode: 2100 V; LC flow rate: 300 nL/min;
Orbitrap scan mode was used for MS/MS, with the resolution 120.000 and the scan range
300–2000 m/z. Peptides were put into dynamic exclusion for 15 s after detected 2 times.
Fragmentation method: CID; Precursor ion isolation width: 1.0 m/z; Maximum injection
time for MS/MS: 100 ms. For analysis with the Lumos, around 5 μL (500 ng) of each sample
was loaded onto the trap column (Acclaim PepMap 100, 75 μm × 2 cm, nanoViper, Thermo
Scientific) using formic acid (0.1%) and resolved in the rapid separation liquid chromatog-
raphy (RSLC) column (Acclaim PepMap RSLC C18, 75 μm × 15 cm, nanoViper, Thermo
Scientific). The samples were eluted using an 85 min linear gradient of ACN (4–45%) in
0.1% formic acid. The parameters for the method created for all Lumos experiments were as
follows: nanospray needle voltage in positive mode: 1950 V; column flow rate: 300 nL/min
and loading pump flow: 1.5 μL/min for 20 min; Inject mode: μL PickUp. Orbitrap scan
mode was used for MS, with the resolution 120.000 and the scan range 375–1500 m/z. Pep-
tides were put into dynamic exclusion for 30 s after detected twice. Detector type for MS/
MS was set to: Orbitrap, with the resolution: 30000, isolation mode: quadrupole (isolation
window of 1.6 Da), activation type: HCD, HCD collision energy: 40%, first mass: 110 m/z.
Stainless steel emitters were purchased from ThermoFisher (O.D. 150 μm, I.D. 30 μm, 40
mm length, inserted in a 1/32 microsleeve for installation).
FANCA regulation of insulin secretion
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Database searching and interactome analysis
The MS/MS spectra from the peptides were searched against the Swiss-Prot database
(Homo sapiens, downloaded at 07/2018, no. of entries = 20387) using MASCOT search
engine (Matrix Science Inc, v2.5.1) [26]. Parameters on MASCOT were set as follows:
Enzyme: trypsin, Max missed cleavage: 2, Peptide charge: 1+ and above, Peptide tolerance:
± 0.1 Da, Fixed modifications: carbamidomethyl (C), Variable modifications: oxidation
(M), phospho (ST) and phospho (Y), MS/MS tolerance: ± 0.5 Da, Instrument: ESI-FTICR.
MASCOT results for different gel cuts of the same sample were combined and analyzed
using Scaffold (Proteome Software Inc., v4.5.1), which allows multiple search results to be
consolidated into a single result file. 99% protein and 50% peptide thresholds were set for
293FT analysis and 99% protein and 95% peptide thresholds for EndoC-βH3 cells. These
settings gave 0.1 and 0.4% protein FDR for 293FT and EndoC-βH3 datasets, respectively,
and 0.0% peptide FDR for both datasets. The interaction specificity between the bait and
prey proteins was assessed with the Significance Analysis of INTeractome (SAINT) algo-
rithm [27], as previously described [28]. All experimental replicates were included in the
proteomic analysis. The molecular interaction networks and functional enrichment analysis
were performed using ClueGO plug-in in Cytoscape (3.6.1). ClueGO was used to analyze
functional enrichments using the Reactome Pathways (20.11.2017) and Reactome Pathways
(20.11.2017) annotations (Min #Gene = 3, Min %Genes = 15%, Kappa Score = 0.4, Two-
sided hypergeometric test, Benjamini-Hochberg p-value correction). ProHits-viz was used
to visualize the output from SAINT [29].
shRNA-mediated silencing of Fanconi anemia proteins
The shRNA sequences from The RNA Consortium library (Sigma-Aldrich) that were used for
the knockdown experiments by lentiviral transduction were either non-targeting scrambled
control shScr (SHC016), FANCA targeting (#1—TRCN0000296799; #2 –TRCN0000291182),
or FANCB targeting (#1 –TRCN0000160916; #2 –TRCN0000163896).
Insulin release assay and glucose/NAC treatment
EndoC-βH3 cells were seeded onto Matrigel-fibronectin coated 12-well TPP plates (MidSci) at
the density of 105 cells/cm2. Four days after cell seeding, lentiviral-mediated knockdown of
FANCA and scrambled control was conducted using the corresponding shRNAs. The next
day, cells were incubated overnight with the glucose-starving Optiβ2 medium (Univercell-Bio-
solutions). Medium was replaced after 24 h with Krebs-Ringer Buffer (KRB-B) (116 mM NaCl,
5.06 mM KCl, 1.01 mM CaCl2, 1.01 mM MgCl2, 1.19 mM KH2PO4, 23.96 mM NaHCO3, 0.1%
BSA, pH 7.4) and incubated for 1 h. Cells were next incubated either with KRB-B3 (KRB-B
with 5 mM glucose), KRB-B3N (KRB-B3 with 5 mM NAC), KRB-B20 (KRB-B with 20 mM
glucose) or KRB-B20N (KRB-B20 with 5 mM NAC) buffer, for 1 h. The medium from each
well was transferred to a micro tube and centrifuged at 700 x g for 5 min at 4˚C. Insulin secre-
tion was measured in the supernatant using STELLUX Chemi Human Insulin ELISA kit
(Alpco) per manufacturer’s instructions. For the intracellular insulin content measurement,
cells were lysed with NETN lysis buffer (250 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 50
mM Tris-HCl, pH 8.0) containing protease inhibitor cocktail (Sigma-Aldrich) and phospha-
tase inhibitors (50 mM NaF, 10 mM β-glycerophosphate, 0.1 mM NaVO4), prior to ELISA
assay. Differences between the insulin concentrations were assessed by either Student’s t-test
or ANOVA using the GraphPad Prism v7.03.
FANCA regulation of insulin secretion
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Cellular ROS detection assay
DCFDA Cellular ROS detection assay kit (Abcam) was used to measure the production of
ROS in the β islet cells at both 5 mM and 20 mM glucose conditions. EndoC-βH3 cells were
seeded onto 96-well microplate at the density of 4 × 105/well and allowed to attach overnight.
Cells were incubated with glucose-starving Optiβ2 medium for 24 h and then incubated with
either KRB-B3 or KRB-B20 buffer (see section Insulin Release Assay and Glucose/NAC treat-
ment) for 1 h. 150 μM tert-butyl hydrogen peroxide (TBHP) solution provided with the kit
was used as a positive control. Cells were next stained with 20 μM DCFDA for 45 min at 37˚C
and the fluorescence signal was read on a microplate reader at Ex/Em: 485/535.
Immunoblot and antibodies
Primary antibodies used were FANCA (A301-980A) (1:2000), FANCD1 (A300-005A)
(1:1000), FANCD2 (A302-174A) (1:2000), FANCE (A302-125A) (1:1000), FANCI (A300-
212A) (1:700), FANCM (A302-637A) (1:1000), FANCO (A302-645A) (1:1000), FANCP
(A302-270A) (1:1000), FANCQ (A301-315A) (1:1000), H2AX (A300-082A) (1:5000) from
Bethyl Laboratories; FANCF (PA5-18202) (1:1000), FANCG (PA5-27117) (1:1000), FANCL
(PA5-19332) (1:1000), PIK3C2A (MA526505) (1:1000), and TFRC (136800) (1:1000) were
from ThermoFisher; β-actin (sc-47778) (1:2000) was from Santa Cruz Biotechnology; FANCS
(OP92-100UG) was from Calbiochem; γ-H2AX (NB100-78356) (1:5000) was from Novus Bio-
logicals. Secondary antibodies used were goat anti-rabbit IgG-HRP (sc-2357) (1:5000), goat
anti-mouse IgG-HRP (sc-2005) (1:5000), and goat anti-rat IgG-HRP (sc-2303) (1:5000) were
from Santa Cruz Biotechnology.
Results
GSIS is impaired following the knockdown of FANCA in human pancreatic
EndoC-βH3 cells
For the purposes of this study, we chose to focus on the FANCA protein, because this gene is
mutated in the majority of FA cases [31]. The EndoC-βH3 pancreas beta islet cell line was gen-
erated by introducing a tamoxifen-inducible CRE-ERT2 construct into the conditionally
immortalized EndoC-βH2 cell line. This led to the development of a β cell line that can be
expanded in culture then reverted to a glucose-responsive, insulin-secreting, proliferation-
arrested β cell with tamoxifen treatment [32]. The EndoC-βH3 is a clear improvement over
other human β cell lines, such as the 1.1B4 cell line generated by electrofusion with pancreatic
ductal adenocarcinoma cell line PANC-1 [33]. To investigate whether FANCA in EndoC-βH3
cells affects GSIS, two FANCA shRNAs were identified capable of knocking down this protein.
Lentivirus shRNAs were generated in 293FT cells and used to transduce EndoC-βH3 cells. The
shRNAs targeting FANCA (shFANCA #1 and #2) were confirmed by western blot of the
EndoC-βH3 cell lysates compared to the non-targeting scrambled control (shScr) (Fig 1A).
The mean normal blood glucose levels in humans is approximately 5.5 mM. Therefore, cells
were cultured in either normal glucose (5 mM) or glucose-stimulated (20 mM) concentrations
for a 1 h treatment period. The results showed that GSIS is significantly impaired after knock-
down of FANCA (Fig 1B). The baseline insulin secretion at 5 mM glucose conditions in the
shFANCA cells did not significantly differ from that of control shScr cells. We observed no dif-
ferences in the intracellular insulin content after the knockdown of FANCA (Fig 1C).
Together, these results suggest the defect in GSIS caused by depletion of FANCA may be
attributed to the disruption of pathways regulating insulin secretion.
FANCA regulation of insulin secretion
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Optimization of the purification and analysis process to evaluate
endogenous FANCA protein-protein interactions in 293FT cells
To develop a comprehensive protein-protein interaction network (PPIN) for FANCA in pan-
creas β cells, the experimental conditions for the immunoprecipitation and enrichment of
endogenous FANCA and its associated protein complexes were first optimized using 293FT
cell lysates. 293FT cells were utilized because they express sufficient amounts of endogenous
FANCA protein and obtaining sufficient protein quantities to perform co-immunoprecipita-
tion (co-IP) experiments is readily achievable compared to human islet purifications from
donor pancreas or β cell lines. Briefly, cell lysates were generated from 293FT cells in culture
and biological duplicate co-IPs were performed using either a non-specific normal rabbit IgG
as a negative control or with anti-FANCA antibody. Immunocomplexes were washed, eluted,
separated by SDS-PAGE and subjected to in-gel digestion with trypsin. Peptides were eluted
and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify
proteins in the sample. High confidence FANCA interactors were distinguished from low con-
fidence and contaminating proteins using non-specific normal rabbit IgG co-IP experiments
(n = 2) along with data deposited in the CRAPome (n = 282) [34] as control dataset inputs into
the Significance Analysis of Interactome (SAINT) algorithm [35] (Fig 2A). A total of 2039 pro-
teins were discovered in the initial FANCA co-IP experiments in 293FT cells by LC-MS/MS
with� 2 peptides identified in at least one of the experiments, but only 137 high confidence
proteins were identified with a SAINT-determined Bayesian false discovery rate (BFDR)�
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Fig 1. Inhibition of FANCA expression disrupts β cell GSIS. A. Confirmation of FANCA knockdown by shRNA (shFANCA #1 and #2) compared to non-
targeting scrambled control shRNA (shScr) in EndoC-βH3 cells. B. GSIS profiles in EndoC-βH3 shScr or shFANCA transduced cells. Paired two-tailed
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Fig 2. Optimization and analysis of the FANCA PPIN in 293FT cells. A. Overview of experimental design to determine the FANCA PPIN in 293FT and EndoC-βH3
cells. All experiments were performed as biological duplicates. B. 137 FANCA protein-protein interactions identified from 293FT lysates. Blue node = FANCA bait,
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https://doi.org/10.1371/journal.pone.0220568.g002
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0.05 and SAINT score� 0.8 (Fig 2B and S1 Table). In the two FANCA-specific co-IP experi-
ments in 293FT cells, FANCA was detected by 106 and 127 total spectra in each biological
duplicate, indicating successful purification of this protein (S1 Table).
Analysis of the functional enrichments present in the 137 high confidence proteins interact-
ing with FANCA was performed using ClueGO interrogation of Reactome Pathways. As
expected, both “DNA Repair” (R-HSA:73894, p-value = 2.0E-7) and the “Fanconi Anemia
Pathway” (R-HSA:6783310, p-value = 1.1E-5) were enriched in this data set (Fig 2C). The
enrichment of these two Reactome pathways was driven, in part, by the known interactions
with other FA protein family members, including FANCB, FANCG, FANCL, FAAP100, and
FAAP20 (Fig 2B and 2D). Known interactions between the 137 FANCA interacting proteins
were mapped using BisoGenet [36] (S1 Fig). ClusterOne [37] was used to identify significantly
interconnected protein complexes, which reveals two clusters of proteins associated with DNA
damage and replication proteins (Cluster #1) or the Fanconi Anemia core complex (Cluster
#2) (Fig 2D). These results confirm known physical associations in the FANCA PPIN dataset
and identify interactions that can explain the co-complexes observed.
Previously unrecognized FANCA interactions with proteins associated with the Reactome
“DNA Repair” term were also identified, such as HERC2, RFC2/4/5, MSH3, and RAD17, sug-
gesting the potential for additional roles of FANCA in DNA damage response (DDR) beyond
those previously reported. The enrichment of other Reactome Pathway terms for the FANCA
interacting proteins, such as “Cellular Response to Heat Stress” (R-HSA:3371556, p-
value = 1.1E-3) and “Loss of Nlp from Mitotic Centrosomes” (R-HSA:380259, p-value = 1.5E-
4), also suggests an expanded role for FANCA beyond its canonical role in the DDR (Fig 2C).
These results confirm that this purification system can enrich FANCA and known protein
interactions, suggesting this method is suitable for implementation in other cell lines.
FANCA displays differential protein interactions in EndoC-βH3 cells in
response to glucose stimulation
Using the conditions optimized in 293FT cells, endogenous FANCA was immunoprecipitated
from EndoC-βH3 cells that were cultured in either 5 mM or 20 mM glucose (Fig 3A). This
experiment identified a total of 3003 proteins in the FANCA PPIN from cells cultured in 5
mM glucose and 2379 proteins from cells cultured in 20 mM glucose with� 2 peptides identi-
fied in at least one of the biological duplicate experiments. SAINT was used to assign and rank
probabilities of these interactions with FANCA. A total of 1417 proteins from both the 5 mM
and 20 mM glucose conditions had a BFDR� 0.05 and SAINT score = 1.0 (S2 Table). Of
these SAINT-filtered interactions, 15% are recalled from the FANCA PPIN cataloged in the
BioGRID database [38] (Fig 3B), which is comparable to the recall rates we have previously
established for large-scale protein interaction analyses of DNA damage proteins [39]. Because
of the availability of the FANCA interactions we identified in 293FT cells, we also analyzed the
recall rates from that dataset (Fig 3C). The FANCA interactions identified in EndoC-βH3 cells
overlapped with 78 of the 137 interactions (57%) identified in the 293FT cells described in Fig
2. Many of the FANCA interactions in EndoC-βH3 cells display differential representation by
their normalized average spectra between the culture conditions (Fig 3D). Statistical analysis
using the Student’s t-test corrected with the Benjamini-Hochberg method identified 210 pro-
teins with elevated representation interacting with FANCA in the 5 mM glucose condition,
whereas 233 were elevated under the 20 mM glucose condition (Fig 3E and 3F). This result
illustrates that the FANCA interactome in EndoC-βH3 cells is both complex and dynamically
regulated in response to glucose stimulation.
FANCA regulation of insulin secretion
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Differential FANCA PPIN identifies functional associations dependent
upon glucose stimulation
The 210 proteins demonstrating elevated interactions with FANCA in the 5 mM glucose con-
dition were analyzed by ClueGO using the Reactome Pathways and Reactions ontology
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datasets. A total of 33 terms were significantly enriched that could be broadly assigned to 6 dif-
ferent major ontology categories after multiple testing correction (S3 Table). The most signifi-
cant term for each of these groups and its corresponding p-value is displayed in Fig 4A. Many
of the proteins associated with these Reactome Pathways and Reactions found interacting with
FANCA at 5 mM glucose are involved in the regulation of gene expression. SMARCA2,
SMARCA4, SMARCC2 are proteins in the SWI/SNF chromatin remodeling complex that reg-
ulate nucleosome positioning involved in the regulation of gene transcription. Both
SMARCA2 and SMARCA4 are tumor suppressors and mutations are frequently found in can-
cers, which may suggest an additional link between FANCA mutations and cancer predisposi-
tion. The proteins EPRS, FARSB, GARS, MARS, RARS, and WARS are involved in tRNA
aminoacylation and implicate FANCA in the regulation of tRNA pools necessary for protein
translation. FANCA interactions with spliceosomal complex proteins also suggest a functional
role in posttranscriptional regulation.
The FANCA interactions identified in the EndoC-βH3 cell line also suggest the potential
for non-canonical protein functions in diverse cellular processes. For instance, FANCA inter-
acts with proteins involved in COPII vesicles involved in the transport of protein cargo from
the rough endoplasmic reticulum (ER) to the Golgi apparatus, such as MIA2, MIA3, PREB,
SEC24B, SEC24C and HLA-A (S3 Table). A ClueGO-based Reactome Pathways and Reactions
analysis was also performed on the 233 FANCA interacting proteins significantly elevated in
the 20 mM glucose condition (S4 Table). Among these 233 proteins, many of the proteins are
those involved in Golgi-related pathways and reactions, such as “synthesis of phosphatidylino-
sitol phosphates (PIPs) at the Golgi membrane”, “dynein-driven retrograde traffic from the
Golgi to the ER”, and “Vamp and trans-Golgi Network AP-1 Binding Coupled with Cargo
Capture” (Fig 4B).
We next examined the gene ontology enrichment for cellular compartment terms for the
proteins with elevated FANCA associations in 20 mM glucose, which identifies intracellular
vesicles as some of the most prominent localizations associated with its interactors (Fig 4C).
Nuclear localization at replication forks were also identified, confirming previous knowledge
of this protein in DNA replication [40]. In addition, “insulin receptor recycling” was a term
significantly associated with a group of 4 V-type proton ATPase subunits involved in the acidi-
fication of intracellular compartments. These proteins all displayed an increased FANCA asso-
ciation in 20 mM glucose (corrected p-value = 8.3E-04) falling in the same ClueGO group
under “transferrin endocytosis and recycling” (S4 Table). Validation of the FANCA interac-
tions with Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha
(PIK3C2A) and Transferrin receptor protein 1 (TFRC) was performed using co-immunopre-
cipitation and western blot analysis (Fig 4D). PIK3C2A is localized to the trans-Golgi network
where it promotes the synthesis of phosphatidylinositol phosphates (PIPs) and is involved in
insulin secretion and signaling [41, 42]. TFRC (also known as CD71) is required for the cellu-
lar uptake of iron and regulates the development of erythrocytes and the nervous system [43,
44]. These results suggest varied roles for FANCA outside of its canonical role in ICL repair.
Glucose stimulation promotes the assembly of the FA core complex
One of the Reactome Pathway terms significantly enriched in response to 20 mM glucose stim-
ulation in the FANCA interaction analysis was “FA core complex assembles at DNA inter-
strand crosslinks (ICLs)” (Fig 4B and S4 Table). This result suggests that glucose stimulation
leads the active assembly of the FA repair complex, which is a process normally induced by
DNA damage. Examination of the FA proteins found in the FANCA interaction data from the
mass spectrometry experiments reveals that glucose stimulation increases the levels of
FANCA regulation of insulin secretion
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FANCG, FANCL, FANCF, FAAP100, FANCE and FANCB interacting with FANCA (Fig 5A).
Notably, FANCB, FANCE, FANCF, and FAAP100 were not identified or did not pass SAINT
filtering in the 5 mM glucose condition but were identifiable in complex with FANCA after
glucose stimulation at 20 mM (Fig 5A). This suggests that the FA core complex is actively
assembling in response to glucose stimulation in EndoC-βH3 cells.
We next sought to examine the effects of increased glucose concentration on the expression
of a panel of FA proteins in EndoC-βH3 cells to determine if the assembly of the FA complex
correlated with protein expression. Glucose stimulation-induced higher expression levels for
FANCA, FANCD1, FANCG, FANCI, FANCM, FANCP, FANCQ, and FANCS (Fig 5B). How-
ever, lowered expression of FANCD2 and FANCE were also observed in 20 mM glucose com-
pared to 5 mM control. No effect was seen on the expression of FANCF, FANCL, or FANCO.
These results indicate that expression of most FA proteins is actively regulated in response to
glucose stimulation. Because the glucose stimulation is only performed for 1 h, this regulation
occurs quite rapidly. The increase in FANCD1 representation in the FANCA pulldown identi-
fied by mass spectrometry might be attributable to elevated protein expression following glu-
cose stimulation (Fig 5B). However, the other FA proteins in complex with FANCA at 20 mM
glucose either do not demonstrate changes in protein expression (FANCE and FANCL) or are
repressed (FANCE) (Fig 5B), suggesting qualitatively that their association with FANCA may
represent the active assembly of the FA complex.
The assembly of the FA complex following glucose stimulation suggests other FA proteins
could also participate in GSIS. To evaluate the role other FA complex proteins in GSIS, we per-
formed a shRNA-mediated knockdown of FANCB in EndoC-βH3 cells (Fig 5C). Like knock-
down of FANCA, the knockdown of FANCB also led to a decrease in GSIS (Fig 5D). The
impaired GSIS was not associated with a decrease in intracellular insulin pools (Fig 5E). It
should be noted that pancreas endocrinopathies are not restricted to a single FA complemen-
tation group, suggesting mutations in different FA genes can lead to beta cell dysfunction. This
is reflected in our results where inhibition of either FANCA or FANCB expression leads to
defects in GSIS.
GSIS requires ROS, which also activates the DDR in EndoC-βH3 cells
In rodent systems, it has been demonstrated that ROS is produced in β cells and is necessary to
promote insulin secretion [45, 46]. We confirmed that ROS levels are increased in response to
glucose stimulation in the human EndoC-βH3 cells (Fig 6A). Pre-incubation with the ROS
scavenger N-acetylcysteine (NAC) for 1 h abolished most insulin secretion at both 5 mM and
20 mM glucose conditions (Fig 6B). These results reveal that ROS is elevated in response to
glucose and is required for the secretion of insulin from the EndoC-βH3 cells.
ROS damage both the DNA nucleobases and the sugar phosphate backbone leading to
many different lesions, including interstrand crosslinks that require the FA pathway for repair
[47]. Therefore, it is possible that glucose stimulation could be inducing DNA damage through
ROS production. Thus, we examined the status of γ-H2AX expression, a marker for DNA
damage, and found that elevated glucose levels promote DNA damage in EndoC-βH3 cells
(Fig 6C). When cells were stimulated with 20 mM glucose and treated with NAC, γ-H2AX lev-
els were reduced in comparison to cells not receiving NAC. These results contrast with
compartment for the 233 proteins with significantly elevated interactions with FANCA in 20 mM glucose conditions. Code = All_without_IEA, GO term fusion, GO
Tree Interval = 3–5, GO Term Selection: minimum number of proteins = 3, minimum percentage of genes = 4%. Right-sided hypergeometric test (enrichment) with
Benjamini-Hochberg p-value correction. D. Co-immunoprecipitation of FANCA from EndoC-βH3 cells confirms the interactions identified with PIK3C2A and TFRC
by western blot.
https://doi.org/10.1371/journal.pone.0220568.g004
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glucose-insensitive MiaPaCa-2 pancreatic ductal adenocarcinoma cells that do not exhibit glu-
cose stimulated DNA damage in the presence or absence of NAC. Together, these results sug-
gest an association between glucose-induced ROS production necessary for insulin release and
increased DNA damage specifically in pancreas β cells.
Discussion
The development of diabetes in FA patients is likely multifactorial. Two potential functions of
FA proteins in β cells that when disrupted in FA patients leads to hyperglycemia are: 1) FA
by shRNA (shFANCB) compared to non-targeting scrambled control shRNA (shScr) in EndoC-βH3 cells. D. GSIS profiles
in EndoC-βH3 shScr or shFANCB transduced cells. Paired two-tailed Student’s t-test p-values are displayed in the
indicated comparisons above the graph. n = 3, mean +/- SEM, n.s. = not statistically significant. E. Intracellular insulin
content of shScr or shFANCB EndoC-βH3 cells used in the GSIS assays in panel C. Paired two-tailed Student’s t-test p-
values are displayed in the indicated comparisons above the graph. n = 3, mean +/- SEM.
https://doi.org/10.1371/journal.pone.0220568.g005
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https://doi.org/10.1371/journal.pone.0220568.g006
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proteins are necessary for GSIS; and 2) FA proteins reduce β cell susceptibility to glucose toxic-
ity. The results from this study suggest a model where FA proteins may function in both pro-
cesses. Knockdown of FANCA or FANCB prevents GSIS in an assay that is performed in an
hour, suggesting loss of FANCA or FANCB has immediate impacts on GSIS not attributable
to glucose toxicity. Glucose toxicity involves cell death mechanisms that would act on a much
longer time scale than the GSIS assay. However, our findings also suggest that glucose stimula-
tion induces the activation of the DDR in an ROS-dependent manner. This data suggests that
β cell dependence on ROS, as a factor necessary for GSIS, exposes islet cells to elevated geno-
toxic stress. In the absence of an intact FA repair pathway, ROS could lead to the accumulation
of DNA damage and cell death. Thus, it is possible that the initial hyperglycemia experienced
in FA patients may be attributable to a defect in GSIS that is further compounded by increased
glucose toxicity of β cells triggered by ROS-induced DNA damage that cannot be repaired.
Our data demonstrates that loss of either FANCA or FANCB in beta cells impairs GSIS, and
glucose stimulation promotes the assembly of the FA complex, suggesting this complex may
have unrecognized roles in beta cell-specific functions.
It should be noted that this study does not attribute the assembly of the FA complex to the
induction of the DNA damage observed upon glucose stimulation. In the western blot analysis,
we did not observe mono-ubiquitination of either FANCI or FANCD2, which are markers of
an active ICL repair response through the FA pathway, following glucose stimulation. Further-
more, the EndoC-βH3 cells are in a growth arrested terminal differentiation state following
addition of 4-OHT and excision of the immortalizing transgenes, which would attenuate DNA
repair processes [48, 49]. Thus, FA complex assembly and the induction of DNA damage
could be either dependent or independent events caused by elevated glucose concentrations.
Decreased response to oxidative stress in FA patients is well-documented and antioxidant
therapy has been postulated as a potential treatment for these patients, but a definitive clinical
benefit has not been demonstrated [50]. The association between FA dysfunction, ROS and
GSIS in beta cells is also unclear. It was previously shown that beta islet cells obtained from
fanca-/- mice did not have a significant increase in cellular ROS compared to wild type con-
trols. Cellular ROS levels in insulin responsive liver, muscle, and fat tissues were also unaf-
fected by fanca status regardless of being fed either a normal or high-fat diet [18]. However,
elevated ROS levels were observed after TNF-alpha treatment in fanca-/- beta islet cells [18].
Elevated levels of TNF-alpha observed in FA patients could increase oxidative stress through
inflammation and ROS production [51]. Treatment of fanca-/- mice with the ROS scavenger
Quercetin can mitigate diabetes and obesity prone phenotypes in part through regulation of
insulin receptor signaling [18]. Moving forward, it will be important to delineate the process
involving ROS production and the assembly of the FA complex induced by glucose
stimulation.
The work presented in this study is the first, to our knowledge, to investigate the endoge-
nous protein interactions with FANCA in endocrine pancreas β cells and how they are altered
upon glucose stimulation. The FANCA PPIN analysis revealed many novel associations
impacted by glucose stimulation including Golgi functions. Interestingly, the Golgi packaging
and transport of insulin prior to exocytosis is a well-established process [52, 53]. Recent evi-
dence also suggests that FA proteins, including FANCA, regulate mitophagy in a process dis-
tinct from their functions in DNA damage repair [54]. Autophagy itself plays an important
role in the regulation of β cell function, and the inhibition of this process results in the devel-
opment of type 2 diabetes [55]. Both autophagy and mitophagy are multistep processes utiliz-
ing autophagosomal membranes that can carry membrane contents from intracellular
organelles including the Golgi apparatus [56]. It should be noted that autophagy proteins were
found to interact with FANCA in our screen of β cells, including ATG2A, ATG4B, and
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ATG9A. Further evaluation of the role of FA proteins in cellular processes involving intracellu-
lar vesicles, such as autophagy and insulin secretory pathways, could shed light on non-canoni-
cal functions of these proteins that contribute to the endocrinopathies in FA patients.
The FANCA PPIN developed here could shed light on some of these processes. For
instance, a correlation has been observed between serum ferritin levels and insulin resistance
in FA patients [57]. Our data suggests that FANCA interacts with proteins involved in trans-
ferrin endocytosis and recycling, such as TFRC, following glucose stimulation. Defects in
FANCA-mediated regulation of transferrin endocytosis and recycling in FA patients could
lead to the accumulation of serum ferritin and contribute to the elevated oxidative stress in
these patients. Furthermore, defects in this pathway caused by loss of FANCA could explain
why FA patients suffer from iron overload and suggests that transfusions used to treat the ane-
mia might not be the only cause of this toxicity. Working with a complete PPIN for FANCA
will allow additional research into how the DNA damage-dependent and independent func-
tions of this protein contributes to the manifestation of the disease that could inform better
treatment strategies for both cancers and co-morbidities that are found in FA patients.
In conclusion, this study identifies FANCA and FANCB as modifiers of GSIS, glucose stim-
ulates the assembly of the FA core complex and establishes a β cell specific FANCA PPIN regu-
lated by glucose stimulation. Together, these results provide new insights into the role of
FANCA in β cells that increase our understanding of FA-associated β cell dysfunction. Work-
ing with a complete PPIN for FANCA will allow additional research into how the DNA dam-
age-dependent and independent functions of this protein contributes to the manifestation of
the disease that could inform better treatment strategies for both cancers and co-morbidities
that are found in FA patients.
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